trial

Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

NCTId NCT05779241
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 83 (actual)
Sponsored by Lyndra Inc.
Primary completion 2023-11-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
83 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2023-04-13
Primary completion
2023-11-03
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
LYN-005Risperidone

Sponsors

Lyndra Inc.Lead Sponsor

Investigators

1
Richard Scranton, MD, MPHPrincipal Investigator

Sites

5 total
Garden Grove, United StatesAtlanta, United StatesChicago, United StatesMarlton, United StatesAustin, United States

Linked catalysts

1
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acti — primary completion2023-11-03

Facts & assertions

4 sourced
Enrollment
83
Phase
PHASE3
Primary Completion Date
2023-11-03
Status
COMPLETED
relationships
The graph out of here
drug
LYN-005
drug
Risperidone
drug
lead_sponsor
Lyndra Inc.
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Richard Scranton, MD, MPH
person